Tigermed plans to privatize Frontage and sell its overseas lab business to focus on China clinical CRO market.

Tigermed announced its plan to privatize its subsidiary Frontage and divest Frontage's overseas laboratory services to Charles River Laboratories and Frontage's chairman, while retaining Frontage's China business. This move allows Tigermed to focus on its core clinical CRO business in China, optimize resources, and improve operational efficiency. The divestment aligns with Tigermed's long-term strategy and is expected to generate proceeds and investment gains, enhancing shareholder value. The privatization and asset restructuring are subject to regulatory approvals and conditions.

Charles River Laboratories (CRL), involved in the acquisition of Frontage's overseas lab services, trades at USD 355.92 on Pluang as of Nov 10, 2026 16:02 WIB, close to its 52-week high of USD 376.10. This price contrasts sharply with its 52-week low of USD 149.93, showing strong market confidence. The stock gained 0.73% in one day, indicating positive investor sentiment around the deal and its health sector position.